BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With a tight lens on late translational through to phase II cl
 inical progress\; the 2nd Chronic HBV Drug Development Summit is dedicate
 d to advancing direct antiviral and immunotherapy pipelines in combinatio
 n therapy paradigms.\n\nThis industry-orientated forum is timely position
 ed after EASL to reset standards after the latest readouts. From dissecti
 ng safe induction of innate and adaptive immune pathways and elucidating 
 the role of T-cells in clearing virus infections\, to clinical progress i
 n combination therapy and assessing durability of surface antigen serocle
 arance\, don’t miss your chance to join the conversation.\n\nHarness acti
 onable insights across 3 days of exclusive content from 20+ scientific ex
 perts including Gilead Sciences\, Vir Biotechnology\, VBI Vaccines\, Alti
 mmune\, Drug Farm\, Replicor and many more to guide your strategic decisi
 ons and drive clinical progress to achieve functional cure for chronic HB
 V.\n
DTEND:20220427T160000
DTSTAMP:20260416T133001Z
DTSTART:20220425T080000
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom Street\, Boston\, Massachu
 setts\, 02114\,
SEQUENCE:0
SUMMARY:With a tight lens on late translational through to phase II clinic
 al progress\; the 2nd Chronic HBV Drug Development Summit is dedicated to
  advancin...
UID:867a8dd0-13f5-47ae-8bdf-94b761c0418f
END:VEVENT
END:VCALENDAR